ADAPTIVE BIOTECHNOLOGIES (ADPT) Stock Price & Overview
NASDAQ:ADPT • US00650F1093
The current stock price of ADPT is 15.93 USD. Today ADPT is down by -3.1%. In the past month the price decreased by -7.92%. In the past year, price increased by 116.74%.
ADPT Key Statistics
- Market Cap
- 2.45B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.40
- Dividend Yield
- N/A
ADPT Stock Performance
ADPT Stock Chart
ADPT Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ADPT. When comparing the yearly performance of all stocks, ADPT is one of the better performing stocks in the market, outperforming 93.96% of all stocks.
ADPT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ADPT. The financial health of ADPT is average, but there are quite some concerns on its profitability.
ADPT Earnings
On February 5, 2026 ADPT reported an EPS of -0.09 and a revenue of 71.68M. The company beat EPS expectations (51.32% surprise) and beat revenue expectations (18.33% surprise).
ADPT Forecast & Estimates
14 analysts have analysed ADPT and the average price target is 21.27 USD. This implies a price increase of 33.55% is expected in the next year compared to the current price of 15.93.
For the next year, analysts expect an EPS growth of -51.09% and a revenue growth 6.68% for ADPT
ADPT Groups
Sector & Classification
ADPT Financial Highlights
Over the last trailing twelve months ADPT reported a non-GAAP Earnings per Share(EPS) of -0.4. The EPS increased by 63.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.29% | ||
| ROE | -39.09% | ||
| Debt/Equity | 0.63 |
ADPT Ownership
ADPT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 20.9 | 192.623B | ||
| DHR | DANAHER CORP | 23.78 | 144.724B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 140.48 | 46.68B | ||
| A | AGILENT TECHNOLOGIES INC | 17.65 | 34.077B | ||
| IQV | IQVIA HOLDINGS INC | 13.64 | 30.168B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 27.28 | 26.158B | ||
| ILMN | ILLUMINA INC | 24.77 | 19.707B | ||
| WAT | WATERS CORP | 21.81 | 18.993B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.13 | 17.902B | ||
| MEDP | MEDPACE HOLDINGS INC | 27.92 | 13.123B | ||
| RVTY | REVVITY INC | 17.56 | 11.167B | ||
| TEM | TEMPUS AI INC-CL A | N/A | 9.169B | ||
| TECH | BIO-TECHNE CORP | 24.89 | 9.051B |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ADPT
Company Profile
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington. The company went IPO on 2019-06-27. The firm is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. The company applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
Company Info
ADAPTIVE BIOTECHNOLOGIES
1165 Eastlake Ave E
Seattle WASHINGTON 98102 US
CEO: Chad Robins
Employees: 619
Phone: 12066590067
ADAPTIVE BIOTECHNOLOGIES / ADPT FAQ
Can you describe the business of ADAPTIVE BIOTECHNOLOGIES?
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington. The company went IPO on 2019-06-27. The firm is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. The company applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
What is the current price of ADPT stock?
The current stock price of ADPT is 15.93 USD. The price decreased by -3.1% in the last trading session.
What is the dividend status of ADAPTIVE BIOTECHNOLOGIES?
ADPT does not pay a dividend.
How is the ChartMill rating for ADAPTIVE BIOTECHNOLOGIES?
ADPT has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of ADAPTIVE BIOTECHNOLOGIES (ADPT)?
ADAPTIVE BIOTECHNOLOGIES (ADPT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.4).
Is ADAPTIVE BIOTECHNOLOGIES (ADPT) expected to grow?
The Revenue of ADAPTIVE BIOTECHNOLOGIES (ADPT) is expected to grow by 6.68% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the next earnings date for ADPT stock?
ADAPTIVE BIOTECHNOLOGIES (ADPT) will report earnings on 2026-04-29, after the market close.